ArticleThe Journal of allergy and clinical immunology2025
Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
Article in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04630652 (Immune Modification of Psoriasis by Selective IL-23 Blockade Using Risankizumab), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immune Modification of Psoriasis by Selective IL-23 Blockade Using Risankizumab
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Integration of GWAS and single-cell analysis for psoriasis identifies disease-associated cell subtypes and therapeutic targets.Nature communications · 2026Pooled it
- Molecular Signature and miRNA Pattern of CD4 + T Lymphocytes in Plaque Psoriasis.Clinical reviews in allergy & immunology · 2026Review
- Mapping the global research landscape of risankizumab: a decade (2016-2025) of multi-database bibliometric analysis and emerging frontiers.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Melittin attenuates imiquimod-induced psoriatic dermatitis in mice: a role for autophagy activation via PI3K/Akt/mTOR pathway suppression.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Spatial transcriptomics maps early B-cell and T-cell activation in hidradenitis suppurativa.The Journal of investigative dermatology · 2026Article
- Lactate reprograms PGE2 metabolism via GPR81 inhibits COX2 to relieved psoriasis.Scientific reports · 2026Article
- Multi‑omics and their integration in psoriasis research (Review).Molecular medicine reports · 2026Review
- Keratinocytes: pleiotropic orchestrators of cutaneous immunity and Inflammation - Emerging therapeutic paradigms in dermatological pathologies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Immunomodulatory Effects of a Tick Salivary Serpin on Psoriasis-like Inflammation.Life (Basel, Switzerland) · 2026Article
- Article
- Clinical value of IL-17-targeted intervention in tissue injury repair: from bidirectional mechanisms to therapeutic strategies.Frontiers in immunology · 2026Review
- T helper 17 cells and group 3 innate lymphoid cells define a spectrum of psoriasis endotypes.Frontiers in immunology · 2026Review
- A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.American journal of clinical and experimental immunology · 2026Review
- Impact of dermatology targeted immunotherapies on autoimmune thyroid diseases: cytokine-network crosstalk and thyroid safety.Frontiers in immunology · 2026Review
- Type 17 T-cell subset divergence in hidradenitis suppurativa versus psoriasis: a comparative single-cell transcriptomic analysis.Frontiers in immunology · 2026Article
- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse.Frontiers in immunology · 2026Review
- Single Cell Analysis of pBMCs of Psoriasis patients reveals distinct CD4+ T cell phenotypes associated with response to IL-23 blockade.bioRxiv : the preprint server for biology · 2025Article
- Skin immune microenvironment in psoriasis: from bench to bedside.Frontiers in immunology · 2025Review
- Relative Fat Mass and Psoriasis Risk: Evidence from NHANES 2009-2014.Journal of multidisciplinary healthcare · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRecent single-cell studies indicated that IL-17-producing T cells (T17) have diverse subsets expressing IL-17A, IL-17F, or a combination in human psoriasis skin. However, it is unknown how T17 subsets are differently regulated by IL-23 versus IL-17A blockade.
objectiveWe sought to investigate how systemic monoclonal antibody injections blocking IL-23 versus IL-17A differently modify immune cell transcriptomes in human psoriasis skin.
methodsWe analyzed a total of 93 human skin single-cell libraries, including 42 psoriasis pretreatment lesional skin, 25 psoriasis pretreatment nonlesional skin, 12 psoriasis posttreatment after IL-23 inhibition, 4 psoriasis posttreatment after IL-17A inhibition, and 10 control skin samples. CLINICALTRIALS: gov NCT04630652.
resultsOf the six T17 subsets identified, an IL17A
conclusionsThis study suggests multiple immune mechanisms of how IL-23 inhibition can modify the complex inflammatory environment present in psoriatic skin, highlighting the roles of specific T17 subsets in psoriasis development and background skin protection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.